Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 26;10(3):466.
doi: 10.3390/jcm10030466.

The Effects of Association of Topical Polydatin Improves the Preemptive Systemic Treatment on EGFR Inhibitors Cutaneous Adverse Reactions

Mauro Bavetta  1 , Dionisio Silvaggio  1 , Elena Campione  1 , Pietro Sollena  2 , Vincenzo Formica  3 , Deborah Coletta  3 , Grazia Graziani  4 , Maria Concetta Pucci Romano  5 , Mario Roselli  3 , Ketty Peris  2   6 , Luca Bianchi  1
Affiliations

The Effects of Association of Topical Polydatin Improves the Preemptive Systemic Treatment on EGFR Inhibitors Cutaneous Adverse Reactions

Mauro Bavetta et al. J Clin Med. .

Abstract

Epidermal Growth Factor Receptor inhibitors (EGFRi) are approved as therapeutic options in several solid tumors. Cutaneous papulopustular eruption is the most frequent cutaneous adverse-event (AE), usually treated with emollient or corticosteroids according to toxicity grade. Our study evaluated the efficacy and safety of a topical product containing polydatin, a glycosylated polyphenol, natural precursor of resveratrol showing anti-inflammatory and anti-oxidative activities, for the prevention and treatment of skin papulopustular rash in EGFRi-treated patients. Forty oncologic patients treated with EGFRi were enrolled in two groups: group-A, 20 patients with papulopustular AE, and group-B, 20 patients without cutaneous manifestations. The study consisted of twice-daily application of polydatin cream 1.5% (group-A) and 0.8% (group-B) for 6 months. In group-A patients, we observed at week 4 a remarkable improvement of skin manifestation and quality of life evaluated with National-Cancer-Institute-Common-Terminology-Criteria for Adverse-Events (NCI-CTCAE), Dermatology-Life-Quality-Index (DLQI) score and Visual-Analogue-Scale (VAS) pruritus, with a statistical significance of p < 0.05. None of the patients of group-B developed skin AEs to EGFRi. No cutaneous AEs related to the polydatin product were reported in both groups. Polydatin can be a good topical aid for the prevention and management of papulopustular rash in cancer patients receiving EGFRi, also capable of improving cancer patients' quality of life.

Keywords: EGFR inhibitors; cutaneous adverse events; papulopustular rash; polydatin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders (institutional grant) had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Average values of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) (y) in the various evaluation timings (x). p ≤ 0.05 at W4.
Figure 2
Figure 2
Average values of Dermatologic Quality of Life Questionnaire (DLQI) (y) in the various evaluation timings (x). p ≤ 0.05 at W4.
Figure 3
Figure 3
Average values of Visual Analogue Scale (Pruritus-VAS) (y) in the various evaluation timings (x). p ≤ 0.05 at W4.
Figure 4
Figure 4
(a) Baseline pictures showing a papulopustular eruption of the face and neck due to Epidermal Growth Factor Receptor inhibitors (EGFR inhibitors). (b) Same patient after 4 weeks of treatment with polydatin 1.5% cream.
See this image and copyright information in PMC

References

    1. Mendelsohn J., Baselga J. Epidermal growth factor receptor targeting in cancer. Semin. Oncol. 2006;33:369–385. doi: 10.1053/j.seminoncol.2006.04.003. - DOI - PubMed
    1. Wang Z. ErbB Receptors and Cancer. Methods Mol. Biol. 2017;1652:3–35. - PubMed
    1. Karamouzis M.V., Grandis J.R., Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA. 2007;298:70–82. doi: 10.1001/jama.298.1.70. - DOI - PubMed
    1. Li J., Yan H. Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: A meta-analysis of 65 randomized controlled trials. Cancer Chemother. Pharmacol. 2018;82:571–583. doi: 10.1007/s00280-018-3644-2. - DOI - PubMed
    1. Li T., Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol. 2009;4:107–119. doi: 10.1007/s11523-009-0114-0. - DOI - PubMed

LinkOut - more resources